Mode of regulatory applications of drugs used off-label reviewed by the evaluation committee on unapproved or off-labeled drugs with high medical needs

Tomomi Ito, Hisashi Urushihara, Yukiko Matsushima, Keitaro Nakajima, Tatsuo Kurokawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The Evaluation Committee on Unapproved or Off-labeled Drugswith High Medical Needs(the Committee)was launched in 2009 to address the issue of unapproved drugs or off-label uses of drugs that are approved in the other developed countriesbut not in Japan. The Committee evaluateswhether a proposed drug or treatment meetshigh medical needs by reviewing the formal petitions submitted by patient advocacy groups, academic societies, and pharmaceutical companies. Based on the review of the Committee, the Ministry of Health, Labour and Welfare (MHLW)determines the mode of regulatory authorization process. Especially for unapproved use of an approved drug, the MHLW decideswhether the use meetsthe criteria foräbbreviated application of publicly known but unapproved indicationc. If applicable, the marketing authorization holder can submit a dossier for the abbreviated application, which includesexis ting data generated from clinical practice without additional clinical trial data. If the drug doesnot meet the criteria, new data from additional registered clinical trialsare usually required. Asof June 2014, the MHLW gave decisionson the mode of regulatory processfor 174 petitionss ubmitted to the Committee during the first and the second public recruitments for drug development. We reviewed these documents to determine which factors were associated with the decision of abbreviated application. Among 59 petitions received in the second recruitment providing detailed background and reasons necessitating the development, 21 petitions provided the data of domestic investigator-initiated prospective trials. Seventeen of the 21 petitions were determined to be valid for abbreviated application, indicating a strong association with the presence of domestic clinical trial data. On the other hand, regulatory approval in other developed countries, despite being a prerequisite for abbreviated application, was inversely associated with actual designation of the abbreviated application. The clinical data required for designation of the abbreviated application are not aswell controlled asone derived from conventional clinical trial data, and consequently are expected to have a lower evidence level. The abbreviated application strategy should be cautiously employed while the issue of drug lag is being resolved gradually in Japan.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume46
Issue number5
Publication statusPublished - 2015

Fingerprint

Pharmaceutical Preparations
Clinical Trials
Japan
Health
Tolnaftate
Pharmaceutical Societies
Off-Label Use
Patient Advocacy
Advisory Committees
Marketing
Developed Countries
Research Personnel
Therapeutics

Keywords

  • Abbreviated Application
  • Drug Lag
  • Off-Label Use
  • Regulatory Application

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Mode of regulatory applications of drugs used off-label reviewed by the evaluation committee on unapproved or off-labeled drugs with high medical needs. / Ito, Tomomi; Urushihara, Hisashi; Matsushima, Yukiko; Nakajima, Keitaro; Kurokawa, Tatsuo.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 46, No. 5, 2015, p. 233-241.

Research output: Contribution to journalArticle

@article{fb528fd9987949f08c5c33dc977f0e22,
title = "Mode of regulatory applications of drugs used off-label reviewed by the evaluation committee on unapproved or off-labeled drugs with high medical needs",
abstract = "The Evaluation Committee on Unapproved or Off-labeled Drugswith High Medical Needs(the Committee)was launched in 2009 to address the issue of unapproved drugs or off-label uses of drugs that are approved in the other developed countriesbut not in Japan. The Committee evaluateswhether a proposed drug or treatment meetshigh medical needs by reviewing the formal petitions submitted by patient advocacy groups, academic societies, and pharmaceutical companies. Based on the review of the Committee, the Ministry of Health, Labour and Welfare (MHLW)determines the mode of regulatory authorization process. Especially for unapproved use of an approved drug, the MHLW decideswhether the use meetsthe criteria for{\"a}bbreviated application of publicly known but unapproved indicationc. If applicable, the marketing authorization holder can submit a dossier for the abbreviated application, which includesexis ting data generated from clinical practice without additional clinical trial data. If the drug doesnot meet the criteria, new data from additional registered clinical trialsare usually required. Asof June 2014, the MHLW gave decisionson the mode of regulatory processfor 174 petitionss ubmitted to the Committee during the first and the second public recruitments for drug development. We reviewed these documents to determine which factors were associated with the decision of abbreviated application. Among 59 petitions received in the second recruitment providing detailed background and reasons necessitating the development, 21 petitions provided the data of domestic investigator-initiated prospective trials. Seventeen of the 21 petitions were determined to be valid for abbreviated application, indicating a strong association with the presence of domestic clinical trial data. On the other hand, regulatory approval in other developed countries, despite being a prerequisite for abbreviated application, was inversely associated with actual designation of the abbreviated application. The clinical data required for designation of the abbreviated application are not aswell controlled asone derived from conventional clinical trial data, and consequently are expected to have a lower evidence level. The abbreviated application strategy should be cautiously employed while the issue of drug lag is being resolved gradually in Japan.",
keywords = "Abbreviated Application, Drug Lag, Off-Label Use, Regulatory Application",
author = "Tomomi Ito and Hisashi Urushihara and Yukiko Matsushima and Keitaro Nakajima and Tatsuo Kurokawa",
year = "2015",
language = "English",
volume = "46",
pages = "233--241",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "5",

}

TY - JOUR

T1 - Mode of regulatory applications of drugs used off-label reviewed by the evaluation committee on unapproved or off-labeled drugs with high medical needs

AU - Ito, Tomomi

AU - Urushihara, Hisashi

AU - Matsushima, Yukiko

AU - Nakajima, Keitaro

AU - Kurokawa, Tatsuo

PY - 2015

Y1 - 2015

N2 - The Evaluation Committee on Unapproved or Off-labeled Drugswith High Medical Needs(the Committee)was launched in 2009 to address the issue of unapproved drugs or off-label uses of drugs that are approved in the other developed countriesbut not in Japan. The Committee evaluateswhether a proposed drug or treatment meetshigh medical needs by reviewing the formal petitions submitted by patient advocacy groups, academic societies, and pharmaceutical companies. Based on the review of the Committee, the Ministry of Health, Labour and Welfare (MHLW)determines the mode of regulatory authorization process. Especially for unapproved use of an approved drug, the MHLW decideswhether the use meetsthe criteria foräbbreviated application of publicly known but unapproved indicationc. If applicable, the marketing authorization holder can submit a dossier for the abbreviated application, which includesexis ting data generated from clinical practice without additional clinical trial data. If the drug doesnot meet the criteria, new data from additional registered clinical trialsare usually required. Asof June 2014, the MHLW gave decisionson the mode of regulatory processfor 174 petitionss ubmitted to the Committee during the first and the second public recruitments for drug development. We reviewed these documents to determine which factors were associated with the decision of abbreviated application. Among 59 petitions received in the second recruitment providing detailed background and reasons necessitating the development, 21 petitions provided the data of domestic investigator-initiated prospective trials. Seventeen of the 21 petitions were determined to be valid for abbreviated application, indicating a strong association with the presence of domestic clinical trial data. On the other hand, regulatory approval in other developed countries, despite being a prerequisite for abbreviated application, was inversely associated with actual designation of the abbreviated application. The clinical data required for designation of the abbreviated application are not aswell controlled asone derived from conventional clinical trial data, and consequently are expected to have a lower evidence level. The abbreviated application strategy should be cautiously employed while the issue of drug lag is being resolved gradually in Japan.

AB - The Evaluation Committee on Unapproved or Off-labeled Drugswith High Medical Needs(the Committee)was launched in 2009 to address the issue of unapproved drugs or off-label uses of drugs that are approved in the other developed countriesbut not in Japan. The Committee evaluateswhether a proposed drug or treatment meetshigh medical needs by reviewing the formal petitions submitted by patient advocacy groups, academic societies, and pharmaceutical companies. Based on the review of the Committee, the Ministry of Health, Labour and Welfare (MHLW)determines the mode of regulatory authorization process. Especially for unapproved use of an approved drug, the MHLW decideswhether the use meetsthe criteria foräbbreviated application of publicly known but unapproved indicationc. If applicable, the marketing authorization holder can submit a dossier for the abbreviated application, which includesexis ting data generated from clinical practice without additional clinical trial data. If the drug doesnot meet the criteria, new data from additional registered clinical trialsare usually required. Asof June 2014, the MHLW gave decisionson the mode of regulatory processfor 174 petitionss ubmitted to the Committee during the first and the second public recruitments for drug development. We reviewed these documents to determine which factors were associated with the decision of abbreviated application. Among 59 petitions received in the second recruitment providing detailed background and reasons necessitating the development, 21 petitions provided the data of domestic investigator-initiated prospective trials. Seventeen of the 21 petitions were determined to be valid for abbreviated application, indicating a strong association with the presence of domestic clinical trial data. On the other hand, regulatory approval in other developed countries, despite being a prerequisite for abbreviated application, was inversely associated with actual designation of the abbreviated application. The clinical data required for designation of the abbreviated application are not aswell controlled asone derived from conventional clinical trial data, and consequently are expected to have a lower evidence level. The abbreviated application strategy should be cautiously employed while the issue of drug lag is being resolved gradually in Japan.

KW - Abbreviated Application

KW - Drug Lag

KW - Off-Label Use

KW - Regulatory Application

UR - http://www.scopus.com/inward/record.url?scp=84957565093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957565093&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84957565093

VL - 46

SP - 233

EP - 241

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 5

ER -